Background/aims: Gastroesophageal reflux disease is one of the most common gastrointestinal diseases of adulthood. Hypersensitive esophagus is a new term which defines patients with reflux symptoms, negative endoscopic findings and normal acid contact time on 24 hour pH analysis, although there is a convincing relationship between symptoms and acid reflux episodes on pH analysis- positive symptom index. In this study, the frequency of hypersensitive esophagus among patients with heartburn was determined and demographic findings, symptoms, manometric and pHmetric findings were compared among hypersensitive esophagus, non-erosive reflux disease, erosive reflux disease and normals.
Methods: Patients admitted to hospital with heartburn and without any cardiac, severe gastric or duodenal pathologies (except minimal antral gastritis) and with no abnormal manometric findings suggestive of esophageal motility disorders were included in the study. All patients were questioned about age, height, weight, educational status and intestinal and extraintestinal reflux related symptoms. Upper endoscopy, esophageal manometry and 24 hour pH monitoring were performed respectively.
Results: Of the 44 patients (17 male, 27 female) included in the study, seven (16%) had hypersensitive esophagus, 15 (34%) had non-erosive reflux disease, seven (16%) had erosive reflux disease and 15 (34%) had normal findings. The female ratio in the hypersensitive esophagus and normal groups was higher while the male ratio was higher in erosive reflux disease. There was no significant difference among groups according to age, body mass index and symptoms. There was also no significant difference according to manometric findings. De Meester scores were significantly lower in hypersensitive esophagus and normal groups while symptom index was highest in the hypersensitive esophagus group. Reflux was observed especially in the upright position in all groups.
Conclusion: The ratio of hypersensitive esophagus, gastroesophageal reflux disease and no pathology in patients with heartburn was 16%, 50% and 34% respectively. It would be appropriate to accept hypersensitive esophagus as a subgroup of reflux disease as it has both symptoms and some manometric and pHmetric changes.
Download full-text PDF |
Source |
---|
Dis Esophagus
January 2025
Department of Medicine, Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CAUSA.
Data on Barrett's esophagus (BE) and esophageal cancer (EC) outcomes in patients with eosinophilic esophagitis (EoE) are limited. We aimed to determine the risk of prevalent BE (<1 year after endoscopy), incident BE (≥1 year after endoscopy), and incident EC in patients with versus without EoE, and to identify predictors of BE/EC in EoE patients. We identified adult patients in the Merative MarketScan Database who underwent first-time upper endoscopy between 2008 and 2020.
View Article and Find Full Text PDFAm J Gastroenterol
January 2025
Kennth C. Griffin Esophageal Center, Division of Gastroenterology and Hepatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Acta Gastroenterol Belg
January 2025
Pediatric gastroenterology, Ghent university hospital, Ghent, Belgium.
Harefuah
December 2024
Eosinophilic Gastrointestinal Disease Clinic, Gastroenterology and Hepatology Unit in collaboration with Immunology and Allergy Unit, Bnai Zion Medical Center, Haifa.
Eosinophilic esophagitis (EoE) is a chronic inflammatory disease of the esophagus, which is mediated by Th2 cells that could start at any age, from early childhood to adulthood. The pathogenesis of the disease is not fully understood, but apparently it consists of a combined interaction between hereditary and environmental factors. Over the years, EoE has become an increasingly diagnosed disease in the context of esophageal symptoms.
View Article and Find Full Text PDFAliment Pharmacol Ther
February 2025
Department of Medicine, Division of Gastroenterology and Hepatology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, USA.
Background: EsoCap is a thin mucoadhesive film designed to target the oesophageal mucosa. The device loaded with mometasone furoate (ESO-101) is under investigation for the treatment of eosinophilic oesophagitis (EoE).
Aims: To evaluate the efficacy, safety and tolerability of ESO-101 in patients with active EoE.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!